Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
OBJECTIVE
To evaluate the survival of patients with advanced epithelial ovarian carcinoma in relation to MIB-1 immunostaining, to determine the association between MIB-1 and clinicopathologic variables, and to identify an appropriate cut-off point for MIB-1 immunostaining as a prognostic marker.


METHODS
We retrospectively reviewed the medical records of women diagnosed with advanced epithelial ovarian carcinoma during 1987-1998. The paraffin-embedded tissue of recruited women was stained with MIB-1 immunostaining for review.


RESULTS
The records of 105 patients were included. The percentage staining of MIB-1 ranged from 0.3 to 100%, with a median of 11.9%. MIB-1 staining was generally higher in serous tumors than in other types (P = 0.048), but was not associated with other potential prognostic indicators. The 5-year survival rate among advanced epithelial ovarian carcinoma patients was 25.7%, while that in the high MIB-1 (greater than or equal to median) and low MIB-1 (less than median) patients was 15.1% (95% confidence interval [CI] = 7.1-26.0) and 36.5% (95% CI = 23.8-49.4), respectively. Median survival times in the two groups were 1.8 years and 3.0 years, respectively (P < 0.008). Division of the MIB-1 staining percentage into quartiles showed that the risk of death increased from the first to the second quartile (>/=7.6 to <11.9%, hazard ratio = 2.36, 95% CI = 1.22-4.54) with no further increase in higher quartiles.


CONCLUSIONS
Among patients with advanced epithelial ovarian carcinoma, MIB-1 immunostaining was higher in serous than in other histologic types. Levels of MIB-1 staining above the cut-off point of 7.6% had significantly poorer survival.
Kritpracha
Krittaya
K
Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Hanprasertpong
Jitti
J
Chandeying
Verapol
V
Dechsukhum
Chawaboon
C
Geater
Alan
A
D018262:Adenocarcinoma, Clear Cell / Q000401:mortality / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000401:mortality / Q000473:pathology; D018269:Carcinoma, Endometrioid / Q000401:mortality / Q000473:pathology; D049109:Cell Proliferation; D018284:Cystadenocarcinoma, Serous / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen; D008499:Medical Records; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D013785:Thailand / Q000453:epidemiology
D019394:Ki-67 Antigen